Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Northwest Biotherapeutics (NWBO) over the last 15 years, with Sep 2025 value amounting to $1.3 million.

  • Northwest Biotherapeutics' Change in Accured Expenses fell 60.45% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 560.27%. This contributed to the annual value of $8.9 million for FY2024, which is 299.66% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Change in Accured Expenses stood at $1.3 million for Q3 2025, which was down 58.18% from $3.2 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Change in Accured Expenses peaked at $5.0 million during Q3 2021, and registered a low of -$7.1 million during Q4 2023.
  • Moreover, its 3-year median value for Change in Accured Expenses was $1.2 million (2023), whereas its average is $1.2 million.
  • In the last 5 years, Northwest Biotherapeutics' Change in Accured Expenses tumbled by 622.56% in 2023 and then soared by 640.58% in 2024.
  • Northwest Biotherapeutics' Change in Accured Expenses (Quarterly) stood at -$3.0 million in 2021, then surged by 145.12% to $1.4 million in 2022, then plummeted by 622.56% to -$7.1 million in 2023, then spiked by 105.64% to $402,000 in 2024, then crashed by 60.45% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $3.2 million for Q2 2025, and $4.4 million during Q1 2025.